Changes in Beneficial Ownership · 4
Nuvectis Pharma, Inc.
NVCTNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
tm2619552-1_4seq1.xml
Filing details
- Report period
- 2026-06-30
- Issuer
- Nuvectis Pharma, Inc.
- Issuer CIK
- 0001875558
- Trading symbol
- NVCT
Reporting owner 1
- Name
- BENTSUR RON
- Reporting owner CIK
- 0001251213
- Relationship
- Director · Officer · 10% owner
- Officer title
- Chairman & CEO
- Address
- C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE, NJ, 07024
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-06-30 | P · Form 4 | 12,500[F1] | A | 20 | 3,688,424[F2] | D |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- D
- Direct
Footnotes
Signature 1
- Signed
- /s/ Ron Bentsur
- Date
- 2026-07-01
Company context
Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company’s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP900 and NXP200, in development for the treatment of advanced cancers.